

What is claimed is:

1. A recombinant avian herpesvirus comprising a herpes virus of turkeys unique long and repeat viral genome region and a Marek's disease virus unique short viral genome region wherein at least one foreign DNA sequence is inserted within a US2 gene of the unique short region of the recombinant avian herpesvirus and is capable of being expressed in a host cell.

2. The recombinant avian herpesvirus of claim 1 wherein the foreign DNA sequence is selected from the group consisting of: a Newcastle disease virus fusion gene, an infectious laryngotracheitis virus glycoprotein D gene, or an infectious laryngotracheitis glycoprotein I gene.

3. The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequence is the Newcastle disease virus fusion gene.

4. The recombinant avian herpesvirus of claim 3 designated NAHV/NDV 295-93 (ATCC Accession number VR_____).

5. The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequence is the infectious laryngotracheitis virus glycoprotein D gene.

6. The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequence is the infectious laryngotracheitis virus glycoprotein I gene.

7. The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequences are the infectious laryngotracheitis virus glycoprotein D gene and the infectious laryngotracheitis virus glycoprotein I gene.

8. The recombinant avian herpesvirus of claim 7 designated NAHV/ILT 295-149 (ATCC Accession number VR_____).

9. The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequences are the Newcastle disease virus fusion gene, the infectious laryngotracheitis virus glycoprotein D gene and the infectious laryngotracheitis virus glycoprotein I gene.

10. The recombinant avian herpesvirus designated NAHV 295-01 (ATCC Accession number VR_____).

11. A vaccine for protecting against Newcastle disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 3 and a suitable carrier.

12. A vaccine for protecting against Newcastle disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 4 and a suitable carrier.

13. A vaccine for protecting against infectious laryngotracheitis comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 7 and a suitable carrier.

14. A vaccine for protecting against infectious laryngotracheitis comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 8 and a suitable carrier.

15. A vaccine for protecting against Marek's disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 10.

16. A multivalent vaccine for protecting against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 9 and a suitable carrier.

17. A multivalent vaccine for protecting against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising, as a mixture, an effective immunizing amount of a first recombinant avian herpesvirus, designated NAHV/ILT

295-149 (ATCC Accession number VR____), an effective immunizing amount of a second recombinant avian herpesvirus, designated NAHV/NDV 295-93 (ATCC Accession number VR____), and a suitable carrier.

18. A method of immunizing an avian species against Newcastle disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 11.

19. A method of immunizing an avian species against Newcastle disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 12.

20. A method of immunizing an avian species against infectious laryngotracheitis comprising administering to the avian species an effective immunizing amount of the vaccine of claim 13.

21. A method of immunizing an avian species against infectious laryngotracheitis comprising administering to the avian species an effective immunizing amount of the vaccine of claim 14.

22. A method of immunizing an avian species against Marek's disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 15.

23. A method of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 16.

24. The vaccine as in claim 11 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

25. The vaccine as in claim 13 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

26. The vaccine as in claim 15 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

27. The vaccine as in claim 16 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

28. The method of claim 18, wherein the vaccine is administered by injection.

29. The method of claim 20, wherein the vaccine is administered by injection.

30. The method of claim 22, wherein the vaccine is administered by injection.

31. The method of claim 23, wherein the vaccine is administered by injection.

32. The method of claim 18, wherein the vaccine is administered intraocularly.

33. The method of claim 20, wherein the vaccine is administered intraocularly.

34. The method of claim 22, wherein the vaccine is administered intraocularly.

35. The method of claim 23, wherein the vaccine is administered intraocularly.

36. The method of claim 18, wherein the vaccine is administered orally.

37. The method of claim 20, wherein the vaccine is administered orally.

38. The method of claim 22, wherein the vaccine is administered orally.

39. The method of claim 23, wherein the vaccine is administered orally.